Cidofovir
Catalog No.S1516 Synonyms: HPMPC
Molecular Weight(MW): 279.19
Cidofovir suppresses virus replication by selective inhibition of viral DNA synthesis.
Cited by 2 Publications
2 Customer Reviews
-
The copy numbers of the intracellular viral DNA were directly extracted from cells and were quantified by qPCR using primers specific for the KSHV ORF73 gene. Then each sample was normalized to the amount of the GAPDH gene (C), CDV (20 µM) was used as a positive control. CDV:Cidofovir.
Viruses 2015, 7, 2268-2287. . Cidofovir purchased from Selleck.
Triptolide reduces lytic and latent replication of KSHV in BCBL-1 cells. Uninduced and induced BCBL-1 cells were treated with vehicle control or indicated concentrations of triptolide for 48 h. The whole cell supernatants, genomic DNA and lysates were prepared. (A) The copy numbers of the intracellular viral DNA were quantified by qRT-PCR, each sample was normalized to the amount of the GAPDH gene. *p<0.05, compared to control.
Int J Oncol, 2016, 48(4):1519-30. . Cidofovir purchased from Selleck.
Purity & Quality Control
Choose Selective DNA/RNA Synthesis Inhibitors
Biological Activity
| Description | Cidofovir suppresses virus replication by selective inhibition of viral DNA synthesis. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In vitro |
Cidofovir inhibits human cytomegalovirus (HCMV) infection in cultured cells. Cidofovir is inhibitory to CMV plaque formation even when added to the cells at 48 hr post infection with IC50 of 0.9 μg/mL for Davis and 1.6 μg/mL for AD-169 strains,respectively. [1] Cidofovir also inhibits herpes simplex virus infection. In addition, Cidofovir blocks cell fusion induced by HSV-1 in monkey kidney cells and blocks the expression of HSV-l-specific proteins and the synthesis of viral DNA. [3] |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cell Data |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In vivo | Cidofovir (5 mg/kg/day) subcutaneously for 5 days significantly reduces average virus infectivity titer in blood, spleen, lung and salivary gland in infected guinea pigs. Cidofovir significantly reduces lymphocytosis and average tissue indexe of spleen in infected animals. [2]. Cidofovir suppresses all manifestations (skin lesions, paralysis of the hind legs, and mortality) of hairless mice infected intracutaneously with HSV-1 or HSV-2. The most remarkable feature of Cidofovir is that a single administration of the compound, even as late as 4 days after infection, conferees significant protection against HSV-1 or HSV-2 infection. [4] Cidofovir inhibits growth of the highly aggressive melanoma tumor arising from mouse melanoma B16 cells grafted subcutaneously in C57B16/J mice. [5] |
Protocol
Solubility (25°C)
| In vitro | Water | 12 mg/mL (42.98 mM) |
|---|---|---|
| DMSO | 2 mg/mL (7.16 mM) | |
| Ethanol | Insoluble |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 279.19 |
|---|---|
| Formula | C8H14N3O6P |
| CAS No. | 113852-37-2 |
| Storage | powder |
| in solvent | |
| Synonyms | HPMPC |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03532035 | Not yet recruiting | Adenovirus | Chimerix | August 30 2018 | Phase 2 |
| NCT02931539 | Recruiting | Cytomegalovirus (CMV) | Shire | December 29 2016 | Phase 3 |
| NCT02567149 | Withdrawn | Warts | University of Minnesota - Clinical and Translational Science Institute | June 2016 | Phase 2 |
| NCT02555800 | Unknown status | Recurrent Respiratory Papillomatosis | Centro de Investigación en. Enfermedades Infecciosas Mexico | December 2014 | Phase 2 |
| NCT01816646 | Completed | Blood And Marrow Transplantation | M.D. Anderson Cancer Center|Gilead Sciences | September 2013 | Phase 1 |
| NCT01946009 | Completed | HIV | Fundacion SEIMC-GESIDA | September 2013 | Not Applicable |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
